About US
Contact us
-
Kerry to Expand Center of Excellence with New Cell Science Laboratory Serving Bio-Pharma Customers GloballyNews Release Please contact: Jim Egan 608.363.1200 jim.egan@kerry.com www.kerry.com Kerry to Expand Center of Excellence with New Cell Science Laboratory Serving Bio-Pharma Customers Glob2012/2/8
-
Drugmakers aim to dampen risks in slow-paying countriesAt first, the mere fact that troubled European countries were deep in debt to drugmakers was news. Then, it was the mounting size of those pharma debts and that Greece, at least, was paying its drug2012/2/7
-
Lilly hunkers down for lean years with salary freezeEli Lilly($LLY), languishing in the doldrums of its long-expected "Years YZ," has frozen the salaries of many of its staffers, including those oftop management. As Pharmalot reports, the company dis2012/2/7
-
Medicaid proposal would let states figure base pricesMedicaid drug pricing has long been a complicated, murky area. So murky, in fact, that drugmakers found themselves party to dozens of lawsuits alleging that they'd inflated wholesale prices report2012/2/6
-
Is Sanofi destined to be 'small player' in MS?Sanofi ($SNY) CEO Chris Viehbacher(photo) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme. But advances by other companies are making it diffi2012/2/6
-
FDA talks, but doctors don't necessarily listenPoor FDA. It takes flak every time a drug spawns unexpected side effects. But when it tries to warn doctors about those side effects--and offers advice for preventing them--few physicians are listen2012/2/3
-
Gloom for the pharma industry, yes. Doom? NoAstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spat2012/2/3
-
As blockbuster drugs fade, so does TV advertisingThe DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 20072012/2/3
-
FDA's new-drug approvals of 20112011 was a big year for drugmakers seeking to get their innovative products approved, as the FDA blessed 30 new drugs, a 7-year high. Among the lucky ones were Johnson & Johnson ($JNJ) and GlaxoSm2012/2/2
-
Roche results spotlight targeted-drug strategyAfter a series of Big Pharma letdowns, Roche's ($RHHBY) results announcement was a series of positives: An increase in 2011 net income, a sales-growth forecast in the "low to mid-single digits," and2012/2/2